PubMed=19544433; DOI=10.1002/stem.98
Kelly J.J.P., Stechishin O.D.M., Chojnacki A., Lun X.-Q., Sun B.-C., Senger D.L., Forsyth P., Auer R.N., Dunn J.F., Cairncross J.G., Parney I.F., Weiss S.
Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Stem Cells 27:1722-1733(2009)

PubMed=26095605; DOI=10.1016/j.stemcr.2015.05.010; PMCID=PMC4618251
Cusulin C., Chesnelong C., Bose P., Bilenky M., Kopciuk K., Chan J.A.W., Cairncross J.G., Jones S.J.M., Marra M.A., Luchman H.A., Weiss S.
Precursor states of brain tumor initiating cell lines are predictive of survival in xenografts and associated with glioblastoma subtypes.
Stem Cell Reports 5:1-9(2015)

PubMed=30153289; DOI=10.1371/journal.pone.0202860; PMCID=PMC6112648
Yuan A.L., Ricks C.B., Bohm A.K., Lun X.-Q., Maxwell L., Safdar S., Bukhari S., Gerber A., Sayeed W., Bering E.A., Pedersen H., Chan J.A.W., Shen Y.-Q., Marra M.A., Kaplan D.R., Mason W.P., Goodman L.D., Ezhilarasan R., Kaufmann A.B., Cabral M., Robbins S.M., Senger D.L., Cahill D.P., Sulman E.P., Cairncross J.G., Blough M.D.
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
PLoS ONE 13:E0202860-E0202860(2018)